480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions

NCT ID: NCT01403077

Last Updated: 2019-09-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2015-10-31

Brief Summary

This is an initial evaluation of the 480 Biomedical Bioresorbable Scaffold System for the treatment of subjects with de novo native superficial femoral artery lesions.

Conditions

Superficial Femoral Artery Lesions; Atherosclerosis of Femoral Artery

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Scaffold Treatment

Group Type: EXPERIMENTAL

480 Biomedical Bioresorbable Scaffold System

Intervention Type: DEVICE

480 Biomedical Bioresorbable Scaffold System

Interventions

480 Biomedical Bioresorbable Scaffold System

480 Biomedical Bioresorbable Scaffold System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age >/= 18 years

2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1cm distal to the femoral bifurcation and > 3 cm above the knee joint

3. Lifestyle-limiting claudication defined as symptomatic subjects with Rutherford Becker Category 2-3

4. Target lesion native reference vessel diameter 4.6 - 6.0 mm by on-line QVA; target lesion native reference vessel diameter less than 5.0 mm only if lesion residual stenosis is ≤ 25%

5. Lesion length: up to a maximum that can be covered by one 100mm scaffold

6. Target lesion > 50% stenosis or total occlusion

7. Undisturbed flow to the foot via at least 2 patent infrapopliteal vessel on the treated side with one vessel free from > 50% stenosis to the ankle joint

8. Patent common and external iliac; TASC A & B lesions may be successfully treated (<30% residual stenosis) at the time of the index procedure

9. The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Human Research Ethics Committee (HREC) of the respective clinical site

10. The study patient agrees to comply with all required post-procedure follow-up visits

Exclusion Criteria

1. Previously implanted stent(s) or stent graft(s) in the target lesion

2. Previous endovascular treatment of the target lesion

3. Femoral access in the target limb within 30 days of study procedure

4. Target lesion residual stenosis > 30% after pre-dilatation with nominally sized balloon

5. Severely calcified lesions as determined by a balloon deformity during dilatation with a nominally sized balloon inflated at nominal pressure.

6. Acute embolic complication at the trifurcation following pre-dilatation not resolved by aspiration

7. Target vessel contains acute thrombus

8. Aneurysm in target vessel

9. Critical limb ischemia defined as Rutherford-Becker Category 4-6

10. Intolerance, or allergies which cannot be adequately pre-medicated, to the following: aspirin, clopidogrel or ticlopidine, heparin, any scaffold components, contrast agents

11. Life expectancy of less than 12 months

12. Pregnancy or breast feeding (negative pregnancy test within 7 days required in females of child bearing potential)

13. Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease)

14. Renal insufficiency (serum creatinine level > 220 µmol/L, or subject is on dialysis)

15. Immunocompromised

16. Active systemic infection or lower limb infection of any nature

17. WBC < 3,000 cells/mm3

18. Myocardial infarction within the past 1 month

19. Stroke within 3 months

20. Un-controlled Atrial-Fibrillation

21. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

480 Biomedical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Alfred

Melbourne, , Australia

Universitäts Klinikum Graz

Graz, , Austria

Universitaet Freiburg-Bad Krozingen

Freiburg im Breisgau, , Germany

Park Hospital - Heart Center Leipzig

Leipzig, , Germany

RoMed Klinikum Rosenheim

Rosenheim, , Germany

Auckland City Hospital

Auckland, , New Zealand

Countries

Australia; Austria; Germany; New Zealand

Other Identifiers

AVI-SFA2011-01

Identifier Type: -

Identifier Source: org_study_id